Front. Immunol.
Frontiers in Immunology
Front. Immunol.
1664-3224
Frontiers Media S.A.
10.3389/fimmu.2023.1272763
Immunology
Correction
Expression of Concern: The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy
Frontiers Editorial Office
*
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
15
08
2023
2023
14
1272763
04
08
2023
04
08
2023
Copyright © 2023 Frontiers Editorial Office
2023
Frontiers Editorial Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
An Expression of concern on The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy by Portoles JM, Jimenez C, Janeiro D, Lopez-Oliva MO, Ortega-Carrion A, Blanquez D, Arribas L, Gomez C, Diez T, Pascual J and Portero I (2021). Front. Immunol. 11:618202. doi: 10.3389/fimmu.2020.618202
section-in-acceptance
Alloimmunity and Transplantation
With this notice, Frontiers states its awareness of concerns regarding the authorship of “The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy” published on 25 January 2021. Specifically, concerns have been raised that three individuals, Veronica Sánchez Rodríguez, Marianna di Scala, and Javier Dotor, have been excluded from the author list. An investigation was conducted in line with COPE guidelines involving the authors’ institution and the funding body, but unfortunately no conclusion could be reached.
This Expression of Concern was approved by the Chief Editors of Frontiers in Immunology and the Chief Executive Editor of Frontiers. The authors do not agree to this Expression of Concern.